Top global pharmaceutical companies’ weekly international regulatory approvals, licensing & partnerships, M&A, clinical developments, and financial performance — August 3–9, 2026

Below is a summary of international regulatory approvals, licensing & partnerships, mergers & acquisitions, clinical developments, and financial performance for the top 30 global pharmaceutical companies during the week of August 3–9, 2026. International Regulatory Approvals: • AbbVie: On August 4, AbbVie’s Allergan Aesthetics announced that the U.S. FDA has accepted its Biologics License Application (BLA) supplement for BOTOX Cosmetic (onabotulinumtoxinA) for the temporary improvement of moderate-to-severe masseteric hypertrophy appearance in adults caused by masseter muscle activity. The application is supported by two Phase 3 clinical trials (M21-416 and M21-417), both of which met their primary endpoints and demonstrated statistically significant improvements over placebo in severity of masseter prominence. Patient satisfaction was also confirmed: twice as many treated patients reported being “very satisfied” or “satisfied” compared to those in the placebo group. • Sanofi: On August 4, Sanofi announced that the European Commission has approved the extension of the indication for MenQuadfi (meningococcal groups A, C, W, and Y conjugate vaccine) to infants aged six weeks and older for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y. MenQuadfi was previously approved in the EU for individuals aged 12 months and older. This approval is supported by data from the MET58 clinical study. • Takeda: On August 5, Takeda announced that the U.S. FDA has approved ORZEYFUL (oveporexton), an oral orexin receptor type 2 (OX2R) agonist, for the treatment of adult patients with type 1 narcolepsy. The approval is based on results from the Phase 3 FirstLight (TAK-861-3001) and RadiantLight (TAK-861-3002) trials, which demonstrated statistically significant and clinically meaningful improvements across all core symptoms—including excessive daytime sleepiness, cataplexy, and health-related quality of life. ORZEYFUL’s controlled substance classification is currently under review by the U.S. Drug Enforcement Administration (DEA), with a decision expected within 90 days. Oveporexton is a selective oral OX2R agonist that restores orexin signaling by selectively stimulating OX2R, thereby addressing the underlying orexin deficiency associated with type 1 narcolepsy. • Astellas: On August 7, Astellas announced it has submitted a New Drug Application (NDA) to Japanese regulatory authorities seeking approval of fezolinetant, an NK3 receptor antagonist, for the treatment of vasomotor symptoms (VMS)—including hot flashes and night sweats—associated with menopause. The application is supported by Japanese clinical trial data, including two Phase 3 STARLIGHT studies conducted in Japanese women. Fezolinetant is an oral, selective neurokinin 3 receptor (NK3R) antagonist that blocks binding of neurokinin B (NKB) to NK3R on kisspeptin/neurokinin/dynorphin (KNDy) neurons—a pathway involved in thermoregulation.

Q3 Earnings Monitoring Daily Report — October 20, 2026

Official Financial Reports ◆ Special Feature · Dual High Growth ×3 ・Yayun Co., Ltd. (603790): Revenue YoY +47% / QoQ +18%; Net Profit Attributable to Shareholders YoY +141% / QoQ +83%; Net Profit Excluding Non-recurring Gains and Losses YoY +145% / QoQ +85%; 10% daily price limit; listed in 2018 Sector: Basic Chemicals – Chemical Products – Textile Chemicals · Shanghai | Concepts: PEEK Materials Core Business: R&D, manufacturing, and sales of mid-to-high-end dyes and textile auxiliaries; provision of related dyeing & finishing and digital color application technical services Controlling Shareholders: Gu Zhedong, Xie Bing, Zheng Yihua | Employees: 503 Snapshot: Total market cap ¥4.5 billion (fully floated ¥4.5 billion); PE (TTM) 30.4x; PB 3.4x; -27.6% from 52-week high; +17% YTD Quality Indicators: Gross margin (cumulative): 33.6% → 33.8% → 34.0% → 34.8%; ROE 8.6%; ROIC 7.7%; Debt-to-Asset Ratio 26.7%; Net Profit Cash Content 79.9% Shareholding Structure: Institutional holdings account for 3.5% of float; ~9,000 shareholders; 6涨停 (daily 10% limit-ups) in past year Catalysts: 1) Rising prices of basic chemical raw materials have increased intermediate costs, driving broad-based price hikes across dye products. Industry-wide upturn combined with volume growth enabled the company—leveraging its differentiated application technical service advantage—to achieve substantial earnings growth. Future performance hinges on pricing sustainability and downstream demand strength. Quarterly Financials: Quarter 25Q4 26Q1 26Q2 26Q3 (Current) Revenue (¥Bn) 1.89 2.75 2.48 2.92 Revenue YoY -3.5% +21.3% +16.3% +46.9% Revenue QoQ -4.8% +45.1% -9.6% +17.7% Net Profit (¥Bn) 0.06 0.37 0.27 0.49 Net Profit YoY Base ≤0 +33.0% +49.0% +140.5% Net Profit QoQ -68.0% +467.4% -27.4% +82.8% Net Profit Excl. NRG&L (¥Bn) 0.02 0.36 0.25 0.46 Net Profit Excl. NRG&L YoY Base ≤0 +38.8% +45.3% +144.6% Net Profit Excl. NRG&L QoQ -91.3% +2098.5% -30.9% +84.7% ・Galaxy Microelectronics Co., Ltd. (688689): Revenue YoY +49% / QoQ +16%; Net Profit Attributable to Shareholders YoY +156% / QoQ +63%; Net Profit Excluding Non-recurring Gains and Losses YoY +196% / QoQ +74%; 20% daily price limit; listed in 2021 Sector: Electronics – Semiconductors – Discrete Devices · Changzhou | Concepts: Intelligent Driving / Silver Nanomaterials / Domestic Chips / New Energy Vehicles / Sensors | Four companies from the electronics sector included this period Core Business: R&D, wafer fabrication, packaging & testing, and marketing of semiconductor discrete devices Controlling Shareholder: Yang Senmao | Employees: 1,344 Snapshot: Total market cap ¥4.9 billion (fully floated ¥4.9 billion); PE (TTM) 37.9x; PB 2.5x; -58.1% from 52-week high; +16% YTD

Alto Ingredients, Inc. to Release Third Quarter 2026 Financial Results on November 4, 2026

4 days ago

Alto Ingredients Inc will announce its third quarter 2026 financial results after market close on November 4, 2026, followed by a management conference call and webcast.

markets.businessinsider.com

Alto Ingredients, Inc. to Release Third Quarter 2026 Financial Results on November 4, 2026

Investing News Network

Alto Ingredients, Inc. to Release Third Quarter 2026 Financial Results on November 4, 2026

GlobeNewswire

Show all reports

2026-05-06

Alto Ingredients (NASDAQ: ALTO) returns to profit with stronger Q1 2026 margins

2026-05-06

Alto Ingredients: Q1 Earnings Snapshot

2026-05-06